| |
Comment |
 CYP inhbitors
|
CYP1A2 [HSA:1544]
|
 Aciclovir [DG:DG00406]
|
Weak (in vivo) |
Allopurinol
|
Weak (in vivo) |
Amiodarone [DG:DG00204]
|
Weak (in vivo) |
Anastrozole
|
Caffeine
|
Weak (in vivo) |
Cimetidine [DG:DG00017]
|
Weak (in vivo) |
Ciprofloxacin [DG:DG00617]
|
Strong (in vivo) |
Clinafloxacin
|
Daidzein
|
Weak (in vivo) |
Deferasirox
|
Disulfiram
|
Weak (in vivo) |
Echinacea
|
Weak (in vivo) |
Enoxacin [DG:DG00619]
|
Strong (in vivo) |
Etintidine
|
Famotidine
|
Weak (in vivo) |
 D00318 Famotidine (JP17/USP/INN)
|
|
Fluvoxamine [DG:DG00946]
|
Strong (in vivo) |
Grepafloxacin [DG:DG00623]
|
Idrocilamide
|
Methoxsalen
|
Moderate (in vivo) |
Mexiletine [DG:DG00197]
|
Moderate (in vivo) |
Mibefradil [DG:DG00328]
|
Norfloxacin [DG:DG00620]
|
Weak (in vivo) |
Pefloxacin
|
Peginterferon alfa-2a
|
Phenylpropanolamine
|
Moderate (in vivo) |
Pipemidic acid [DG:DG00631]
|
Piperine
|
Propafenone [DG:DG00200]
|
Weak (in vivo) |
Propranolol [DG:DG00305]
|
Weak (in vivo) |
Rofecoxib
|
Stiripentol
|
Terbinafine [DG:DG00375]
|
Weak (in vivo) |
Tiabendazole
|
Moderate (in vivo) |
Ticlopidine
|
Weak (in vivo) |
Vemurafenib
|
Moderate (in vivo) |
Verapamil [DG:DG00329]
|
Weak (in vivo) |
Viloxazine [DG:DG00956]
|
Zafirlukast
|
Zileuton
|
Moderate (in vivo) |
CYP2A6 [HSA:1548]
|
CYP2B6 [HSA:1555]
|
CYP2C8 [HSA:1558]
|
CYP2C9 [HSA:1559]
|
CYP2C19 [HSA:1557]
|
CYP2D6 [HSA:1565]
|
CYP3A4 [HSA:1576]
|
CYP3A5 [HSA:1577]
|
CYP3A7 [HSA:1551]
|
CYP3A [HSA:1576 1577 1551]
|
CYP17 [HSA:1586]
|
|
|
CYP inducers
|
|
|
CYP substrates
|
|
|
Transporter inhibitors
|
ABCB1 [HSA:5243]
|
ABCB4 [HSA:5244]
|
ABCB11 [HSA:8647]
|
ABCC1 [HSA:4363]
|
ABCC2 [HSA:1244]
|
ABCC3 [HSA:8714]
|
ABCC4 [HSA:10257]
|
ABCG2 [HSA:9429]
|
SLC15A2 [HSA:6565]
|
SLCO1A2 [HSA:6579]
|
SLCO1B1 [HSA:10599]
|
SLCO1B3 [HSA:28234]
|
SLCO2B1 [HSA:11309]
|
SLC22A1 [HSA:6580]
|
SLC22A2 [HSA:6582]
|
Cetirizine [DG:DG01107]
|
Cimetidine [DG:DG00017]
|
FDA |
Diphenhydramine [DG:DG00390]
|
Famotidine
|
D00318 Famotidine (JP17/USP/INN)
|
|
Pilsicainide [DG:DG01257]
|
Quinidine [DG:DG00192]
|
FDA |
Ranitidine [DG:DG00018]
|
Testosterone [DG:DG00460]
|
SLC22A3 [HSA:6581]
|
Cimetidine [DG:DG00017]
|
Famotidine
|
D00318 Famotidine (JP17/USP/INN)
|
|
Prazosin [DG:DG00253]
|
Verapamil [DG:DG00329]
|
SLC22A8 [HSA:9376]
|
OAT1 [HSA:9356]
|
OAT2 [HSA:10864]
|
OAT3 [HSA:9376]
|
URAT1 [HSA:116085]
|
MATE1 [HSA:55244]
|
MATE2 [HSA:146802]
|
|
|
Transporter inducers
|
|
|
Transporter substrates
|
ABCB1 [HSA:5243]
|
ABCB4 [HSA:5244]
|
ABCB11 [HSA:8647]
|
ABCC2 [HSA:1244]
|
ABCC3 [HSA:8714]
|
ABCC4 [HSA:10257]
|
ABCG2 [HSA:9429]
|
OAT1 [HSA:9356]
|
Aciclovir [DG:DG00406]
|
Adefovir [DG:DG01224]
|
FDA |
Aminohippuric acid [DG:DG01170]
|
Benzylpenicillin [DG:DG00534]
|
Bumetanide
|
Captopril
|
FDA |
Cefaclor [DG:DG00560]
|
Cidofovir [DG:DG00648]
|
Ciprofloxacin [DG:DG00617]
|
Famotidine
|
D00318 Famotidine (JP17/USP/INN)
|
|
Fexofenadine
|
Furosemide [DG:DG00272]
|
FDA |
Ganciclovir [DG:DG00646]
|
Lamivudine
|
FDA |
Methotrexate [DG:DG00681]
|
FDA |
Oseltamivir [DG:DG00665]
|
FDA |
Tenofovir [DG:DG01223]
|
FDA |
Zalcitabine
|
FDA |
Zidovudine
|
FDA |
OAT2 [HSA:10864]
|
OAT3 [HSA:9376]
|
Aciclovir [DG:DG00406]
|
FDA |
Adefovir [DG:DG01224]
|
Benzylpenicillin [DG:DG00534]
|
FDA |
Bumetanide
|
FDA |
Cefaclor [DG:DG00560]
|
Ceftizoxime [DG:DG00576]
|
Ciprofloxacin [DG:DG00617]
|
FDA |
Famotidine
|
FDA |
D00318 Famotidine (JP17/USP/INN)
|
|
Fexofenadine
|
Furosemide [DG:DG00272]
|
FDA |
Ganciclovir [DG:DG00646]
|
Methotrexate [DG:DG00681]
|
FDA |
Pravastatin [DG:DG00353]
|
FDA |
Rosuvastatin [DG:DG00357]
|
FDA |
Sitagliptin [DG:DG00118]
|
FDA |
Zalcitabine
|
Zidovudine
|
FDA |
SLC15A1 [HSA:6564]
|
SCL15A2 [HSA:6565]
|
SLCO1A2 [HSA:6579]
|
SLCO1B1 [HSA:10599]
|
SLCO1B3 [HSA:28234]
|
SLCO2B1 [HSA:11309]
|
SLC22A1 [HSA:6580]
|
SLC22A2 [HSA:6582]
|
Amantadine [DG:DG00860]
|
FDA |
Amiloride [DG:DG00275]
|
FDA |
Cetirizine [DG:DG01107]
|
Cimetidine [DG:DG00017]
|
FDA |
Cisplatin
|
Creatinine
|
Dopamine [DG:DG00213]
|
FDA |
Famotidine
|
FDA |
D00318 Famotidine (JP17/USP/INN)
|
|
Memantine [DG:DG00986]
|
FDA |
Metformin [DG:DG00113]
|
FDA |
Nafamostat
|
Oxaliplatin
|
Pindolol
|
Pramipexole [DG:DG00863]
|
Procainamide [DG:DG00193]
|
FDA |
Ranitidine [DG:DG00018]
|
FDA |
Varenicline [DG:DG00995]
|
FDA |
Ranitidine [DG:DG00018]
|
Quinine [DG:DG01019]
|
Varenicline [DG:DG00995]
|
SLC22A3 [HSA:6581]
|
SLC28A2 [HSA:9153]
|
SLC28A3 [HSA:64078]
|
SLC29A1 [HSA:2030]
|
SLC29A2 [HSA:3177]
|
MATE1 [HSA:55244]
|
MATE2 [HSA:146802]
|
Drug interactions with metabolizing enzymes and transporters